NEW YORK -- An immunotherapy-chemoradiotherapy (CRT) combination did not boost progression-free survival (PFS) in untreated, locally advanced cervical cancer, according to CALLA trial findings. Newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results